- Home
- DMA vs TCRX Comparison
DMA vs TCRX Comparison
Compare DMA & TCRX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- DMA
- TCRX
- Stock Information
- Founded
- DMA 2011
- TCRX 2018
- Country
- DMA United States
- TCRX United States
- Employees
- DMA N/A
- TCRX N/A
- Industry
- DMA Trusts Except Educational Religious and Charitable
- TCRX Biotechnology: Pharmaceutical Preparations
- Sector
- DMA Finance
- TCRX Health Care
- Exchange
- DMA Nasdaq
- TCRX Nasdaq
- Market Cap
- DMA 70.8M
- TCRX 67.9M
- IPO Year
- DMA N/A
- TCRX 2021
- Fundamental
- Price
- DMA $7.99
- TCRX $1.63
- Analyst Decision
- DMA
- TCRX Strong Buy
- Analyst Count
- DMA 0
- TCRX 6
- Target Price
- DMA N/A
- TCRX $9.83
- AVG Volume (30 Days)
- DMA 34.6K
- TCRX 567.5K
- Earning Date
- DMA 01-01-0001
- TCRX 05-12-2025
- Dividend Yield
- DMA 2.04%
- TCRX N/A
- EPS Growth
- DMA N/A
- TCRX N/A
- EPS
- DMA N/A
- TCRX N/A
- Revenue
- DMA N/A
- TCRX $2,816,000.00
- Revenue This Year
- DMA N/A
- TCRX $47.30
- Revenue Next Year
- DMA N/A
- TCRX $74.30
- P/E Ratio
- DMA N/A
- TCRX N/A
- Revenue Growth
- DMA N/A
- TCRX N/A
- 52 Week Low
- DMA $4.78
- TCRX $1.02
- 52 Week High
- DMA $8.00
- TCRX $9.69
- Technical
- Relative Strength Index (RSI)
- DMA 45.67
- TCRX 58.69
- Support Level
- DMA $7.71
- TCRX $1.02
- Resistance Level
- DMA $8.05
- TCRX $1.36
- Average True Range (ATR)
- DMA 0.33
- TCRX 0.17
- MACD
- DMA 0.03
- TCRX 0.07
- Stochastic Oscillator
- DMA 65.60
- TCRX 93.85
About DMA Destra Multi-Alternative Fund
Destra Multi-Alternative Fund is a non-diversified, closed-end management investment company that operates as an interval fund with a continuous offering of fund shares. The investment objective of the fund is to seek returns from capital appreciation and income with an emphasis on income generation.
About TCRX TScan Therapeutics Inc.
TScan Therapeutics Inc is a biopharmaceutical company focused on the development of T-cell receptor (TCR) engineered T cell therapies (TCR-T) for the treatment of patients with cancer. The company's liquid tumor TCR-T therapy candidates, TSC-100 and TSC-101, are in development for the treatment of patients with hematologic malignancies to eliminate residual leukemia and prevent relapse after hematopoietic stem cell transplantation. It is also developing multiplexed TCR-T therapy candidates for the treatment of various solid tumors.